CMMB
Income statement / Annual
Last year (2023), Chemomab Therapeutics Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Chemomab Therapeutics Ltd.'s net income was -$24.22 M.
See Chemomab Therapeutics Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2012
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2012 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$66,827.00 |
$57,773.00 |
$34,023.00 |
$79,999.00 |
$281,909.00 |
$66,000.00 |
$51,000.00 |
$40,638.00 |
$26,253.00 |
$0.00 |
| Gross Profit |
-$66,827.00 |
-$57,773.00 |
-$34,023.00 |
-$79,999.00 |
-$281,909.00 |
-$66,000.00 |
-$51,000.00 |
-$40,638.00 |
-$26,253.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$18.38 M
|
$16.98 M
|
$6.33 M
|
$4.68 M
|
$13.35 M
|
$7.51 M
|
$6.23 M
|
$2.34 M
|
$5.96 M
|
$15.72 M
|
| General & Administrative
Expenses |
$7.08 M
|
$11.56 M
|
$6.03 M
|
$1.29 M
|
$960,000.00
|
$374,000.00
|
$0.00
|
$0.00
|
$0.00
|
$5.65 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.96 M
|
$5.08 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$7.08 M
|
$11.56 M
|
$6.03 M
|
$1.29 M
|
$5.98 M
|
$5.46 M
|
$3.11 M
|
$2.25 M
|
$1.14 M
|
$5.65 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$749,000.00 |
$3.35 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$25.46 M |
$28.53 M |
$12.37 M |
$5.97 M |
$19.33 M |
$12.97 M |
$9.34 M |
$4.59 M |
$7.11 M |
$21.37 M |
| Cost And Expenses |
$25.46 M |
$28.53 M |
$12.37 M |
$5.97 M |
$19.61 M |
$13.04 M |
$9.39 M |
$4.63 M |
$7.13 M |
$21.37 M |
| Interest Income |
$1.23 M |
$351,618.00 |
$65.00 |
$19,999.00 |
$393,000.00 |
$0.00 |
$1,000.00 |
$521.00 |
$1,029.54 |
$0.00 |
| Interest Expense |
$0.00 |
$353,000.00 |
$111,076.00 |
$6,000.00 |
$9,000.00 |
$0.00 |
$5,000.00 |
$0.00 |
$14,156.00 |
$0.00 |
| Depreciation &
Amortization |
$67,000.00
|
$57,773.00
|
$34,023.00
|
$79,999.00
|
$281,909.00
|
$66,000.00
|
$51,000.00
|
$40,638.00
|
$26,253.00
|
$0.00
|
| EBITDA |
-$25.39 M
|
-$28.48 M
|
-$12.33 M
|
-$5.95 M
|
-$26.92 M
|
-$13.36 M
|
-$9.50 M
|
-$4.57 M
|
-$7.46 M
|
$24.18 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$1.24 M
|
$353,000.00
|
-$111,000.00
|
$21,000.00
|
-$7.60 M
|
-$455,515.00
|
-$164,629.00
|
$20,690.00
|
-$367,793.00
|
$29.24 M
|
| Income Before Tax |
-$24.22 M |
-$28.18 M |
-$12.48 M |
-$5.95 M |
-$27.21 M |
-$13.49 M |
-$9.48 M |
-$4.60 M |
-$7.50 M |
$24.18 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$534,000.00 |
$77,000.00 |
-$21,000.00 |
$1.00 |
$306,000.00 |
$323,000.00 |
$136,241.00 |
-$3.00 |
$0.00 |
| Net Income |
-$24.22 M |
-$27.65 M |
-$12.56 M |
-$5.93 M |
-$27.21 M |
-$13.80 M |
-$9.81 M |
-$4.73 M |
-$7.50 M |
$24.18 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.06 |
-2.43 |
-1.21 |
-3.2 |
-15.8 |
-21.84 |
-217.31 |
-17.42 |
-32.94 |
0.0005 |
| EPS Diluted |
-2.06 |
-2.43 |
-1.21 |
-3.2 |
-15.8 |
-21.84 |
-217.31 |
-17.42 |
-32.94 |
0.0005 |
| Weighted Average Shares
Out |
$11.75 M
|
$11.38 M
|
$10.37 M
|
$1.85 M
|
$1.72 M
|
$631,700.00
|
$45,125.00
|
$271,670.00
|
$227,685.00
|
$50.11 B
|
| Weighted Average Shares
Out Diluted |
$11.75 M
|
$11.38 M
|
$10.37 M
|
$1.85 M
|
$1.72 M
|
$631,700.00
|
$45,125.00
|
$271,670.00
|
$227,685.00
|
$50.11 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
